Project Grant R21AI186020
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$451K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,503,349 to the University of Arkansas for Medical Sciences to conduct research on the ontogeny and metabolism of lung alveolar macrophages and their role in tuberculosis infection. The project aims to determine how the origin and metabolic pathways of these macrophages contribute to their permissiveness to Mycobacterium tuberculosis, and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $185,280 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas A&M University System Health Science Center to study how the Mycobacterium tuberculosis (MTB) secreted protein Rv1075c hijacks host histone methyltransferases to promote infection. The key objectives are to define how histone methylation changes at innate immune genes during MTB infection, and investigate how...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The award aims to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in TB control and reactivation, as well as characterize the cellular mechanisms of BMP pathway activation during TB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $162,000 in funding to The Washington University to conduct research on the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to characterize pDC function during MTB infection to identify potential pDC-specific therapeutic targets that could lead to host-directed...
This Project Grant award of $750,815, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research aimed at developing novel anti-infective strategies to treat pulmonary mucormycosis, a deadly invasive fungal infection. The key objectives are to: 1) examine the role of the host cell hypoxia-response pathway, specifically the protein ANGPTL4, in the pathogenesis of mucormycosis and explore its therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $426,938 to The Johns Hopkins University to develop a simplified and inexpensive mouse model of Mycobacterium abscessus lung disease. The goal is to create a reproducible animal model that can faithfully replicate the efficacy of standard-of-care drugs used to treat this chronic and often incurable lung infection. This...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $611,129 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Terasaki Institute for Biomedical Innovation. This 4-year award, spanning from August 2024 to June 2028, aims to develop and validate a multi-organ-on-a-chip (MOC) platform comprised of a vascularized liver-on-a-chip and heart-on-a-chip model. The MOC platform will integrate a microfluidic electrochemical biosensor...
This federal Project Grant award of $637,275 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the mechanisms by which bacterial pathogens rapidly develop tolerance to chemical stressors, such as antibiotics. The research aims to define novel stress tolerance mechanisms in pathogens, with implications for improving antibacterial therapies and public health. Key focus areas...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop targeted vaccine candidates against nontuberculous mycobacterial (NTM) infections. The project aims to develop an adjuvanted subunit vaccine and a novel replicon RNA-based vaccine against pathogenic NTM strains, which have...